| Drug Name | Ribomustin (Bendamustine ) |
|---|---|
| Drug Class | |
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
increased mortality observed when used in non-approved combination treatments or outside approved indications. |
| Dear Healthcare provider letter DHPC |
|